Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia 2Hematologic Neoplasms 2Stomach Neoplasms 1Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Nose Neoplasms 1Neoplasm, Residual 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Hairy Cell 1Genital Neoplasms, Female 1Esthesioneuroblastoma, Olfactory 1EGFR-Mutated Non-Small-Cell Lung Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1Appendiceal Neoplasms 1Adenocarcinoma 1

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × Electrocardiography × Clear all
NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡